{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"551"},{"groupId":"OG001","value":"535"}]}],"title":"Adverse Events (AEs)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"242"},{"groupId":"OG001","value":"227"}]}],"title":"Serious Adverse Events (SAEs)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"554"},{"groupId":"OG001","value":"548"}],"units":"Participants"}],"description":"The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: all randomized participants who received at least one dose of study medication, according to the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From study treatment start date till 28 days safety follow-up, assessed up to approximately 152 months","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}